Drug Profile
Research programme: GPBAR1 protein agonists - Intercept Pharmaceuticals
Alternative Names: GPBAR1 protein agonists - Intercept Pharmaceuticals; INT-777; S-EMCA; TGR5 protein agonists - Intercept PharmaceuticalsLatest Information Update: 10 Nov 2023
Price :
$50
*
At a glance
- Originator Intercept Pharmaceuticals
- Class Antihyperglycaemics; Bile acids and salts; Cholanes; Obesity therapies; Small molecules
- Mechanism of Action GPBAR1 protein agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Discontinued Diabetes mellitus; Metabolic disorders; Obesity
Most Recent Events
- 08 Nov 2023 Intercept Pharmaceuticals has been acquired by Alfasigma
- 22 Feb 2023 Discontinued - Preclinical for Diabetes mellitus in USA (PO) (Intercept Pharmaceuticals pipeline, February 2023)
- 22 Feb 2023 Discontinued - Preclinical for Metabolic disorders in USA (PO) (Intercept Pharmaceuticals pipeline, February 2023)